536 related articles for article (PubMed ID: 31253185)
1. FDG-PET as an independent biomarker for Alzheimer's biological diagnosis: a longitudinal study.
Ou YN; Xu W; Li JQ; Guo Y; Cui M; Chen KL; Huang YY; Dong Q; Tan L; Yu JT;
Alzheimers Res Ther; 2019 Jun; 11(1):57. PubMed ID: 31253185
[TBL] [Abstract][Full Text] [Related]
2. ¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Smailagic N; Vacante M; Hyde C; Martin S; Ukoumunne O; Sachpekidis C
Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010632. PubMed ID: 25629415
[TBL] [Abstract][Full Text] [Related]
3. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
[TBL] [Abstract][Full Text] [Related]
4. Regional fluorodeoxyglucose metabolism and instrumental activities of daily living across the Alzheimer's disease spectrum.
Roy K; Pepin LC; Philiossaint M; Lorius N; Becker JA; Locascio JJ; Rentz DM; Sperling RA; Johnson KA; Marshall GA
J Alzheimers Dis; 2014; 42(1):291-300. PubMed ID: 24898635
[TBL] [Abstract][Full Text] [Related]
5. Neuronal injury biomarkers for assessment of the individual cognitive reserve in clinically suspected Alzheimer's disease.
Beyer L; Schnabel J; Kazmierczak P; Ewers M; Schönecker S; Prix C; Meyer-Wilmes J; Unterrainer M; Catak C; Pogarell O; Perneczky R; Albert NL; Bartenstein P; Danek A; Buerger K; Levin J; Rominger A; Brendel M
Neuroimage Clin; 2019; 24():101949. PubMed ID: 31398553
[TBL] [Abstract][Full Text] [Related]
6. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
7. Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion.
Lange C; Suppa P; Frings L; Brenner W; Spies L; Buchert R
J Alzheimers Dis; 2016; 49(4):945-959. PubMed ID: 26577523
[TBL] [Abstract][Full Text] [Related]
8. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
[TBL] [Abstract][Full Text] [Related]
9. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
[TBL] [Abstract][Full Text] [Related]
10. Brain PET amyloid and neurodegeneration biomarkers in the context of the 2018 NIA-AA research framework: an individual approach exploring clinical-biomarker mismatches and sociodemographic parameters.
Coutinho AM; Busatto GF; de Gobbi Porto FH; de Paula Faria D; Ono CR; Garcez AT; Squarzoni P; de Souza Duran FL; de Oliveira MO; Tres ES; Brucki SMD; Forlenza OV; Nitrini R; Buchpiguel CA
Eur J Nucl Med Mol Imaging; 2020 Oct; 47(11):2666-2680. PubMed ID: 32055966
[TBL] [Abstract][Full Text] [Related]
11. Regional Disconnection in Alzheimer Dementia and Amyloid-Positive Mild Cognitive Impairment: Association Between EEG Functional Connectivity and Brain Glucose Metabolism.
Smailovic U; Koenig T; Savitcheva I; Chiotis K; Nordberg A; Blennow K; Winblad B; Jelic V
Brain Connect; 2020 Dec; 10(10):555-565. PubMed ID: 33073602
[No Abstract] [Full Text] [Related]
12. What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?
Andriuta D; Moullart V; Schraen S; Devendeville A; Meyer ME; Godefroy O;
J Alzheimers Dis; 2016; 51(3):793-800. PubMed ID: 26923012
[TBL] [Abstract][Full Text] [Related]
13. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
J Alzheimers Dis; 2018; 62(1):399-408. PubMed ID: 29439345
[TBL] [Abstract][Full Text] [Related]
14. MRI or
Doering E; Antonopoulos G; Hoenig M; van Eimeren T; Daamen M; Boecker H; Jessen F; Düzel E; Eickhoff S; Patil K; Drzezga A;
J Nucl Med; 2024 Jan; 65(1):147-155. PubMed ID: 38050112
[TBL] [Abstract][Full Text] [Related]
15. Prognosis of conversion of mild cognitive impairment to Alzheimer's dementia by voxel-wise Cox regression based on FDG PET data.
Sörensen A; Blazhenets G; Rücker G; Schiller F; Meyer PT; Frings L;
Neuroimage Clin; 2019; 21():101637. PubMed ID: 30553760
[TBL] [Abstract][Full Text] [Related]
16. Metabolic correlates of reserve and resilience in MCI due to Alzheimer's Disease (AD).
Bauckneht M; Chincarini A; Piva R; Arnaldi D; Girtler N; Massa F; Pardini M; Grazzini M; Efeturk H; Pagani M; Sambuceti G; Nobili F; Morbelli S
Alzheimers Res Ther; 2018 Apr; 10(1):35. PubMed ID: 29615111
[TBL] [Abstract][Full Text] [Related]
17. Reciprocal Incremental Value of 18F-FDG-PET and Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment Patients Suspected for Alzheimer's Disease and Inconclusive First Biomarker.
Massa F; Farotti L; Eusebi P; Capello E; Dottorini ME; Tranfaglia C; Bauckneht M; Morbelli S; Nobili F; Parnetti L
J Alzheimers Dis; 2019; 72(4):1193-1207. PubMed ID: 31683477
[TBL] [Abstract][Full Text] [Related]
18. The use of individual-based FDG-PET volume of interest in predicting conversion from mild cognitive impairment to dementia.
Huang SH; Hsiao WC; Chang HI; Ma MC; Hsu SW; Lee CC; Chen HJ; Lin CH; Huang CW; Chang CC
BMC Med Imaging; 2024 Mar; 24(1):75. PubMed ID: 38549082
[TBL] [Abstract][Full Text] [Related]
19. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A
J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056
[TBL] [Abstract][Full Text] [Related]
20. Biomarker-Based Prediction of Progression to Dementia: F-18 FDG-PET in Amnestic MCI.
Tripathi M; Tripathi M; Parida GK; Kumar R; Dwivedi S; Nehra A; Bal C
Neurol India; 2019; 67(5):1310-1317. PubMed ID: 31744965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
